Objective To assess on-treatment serum HBsAg and HBV DNA kinetics in HBeAg-positive CHB patients to predict the efficacy of pegylated interferon (PEG-IFN) in early phase of treatment. Methods Forty-one treatment-naive HBeAg-positive patients treated with PEG-IFNα 2a at a dose of 180 μg/week for at least 24 weeks were evaluated. Their treatment response was assessed, including normalization of serum ALT, decline of serum HBV DNA and loss of HBeAg. Results We found that a decrease of HBV DNA level at the 4th week was positively correlated with the decrease of HBV DNA level at the 12th week and 24th week (r = 0.8202, P < 0.0001 and r = 0.6838, P < 0.0001, respectively). We observed that a decrease of HBsAg level at the 4th week was positively correlated with decrease of HBsAg level at the 12th week and 24th week (r = 0.4868, P = 0.0023 and r = 0.4251, P = 0.0109, respectively). A decrease of HBsAg level at the 24th week was positively correlated with the decrease of HBV DNA level at the 24th week (r = 0.5262, P = 0.0024). Serum level of IFN and IFN neutralizing antibody had no relationship with HBV DNA or HBsAg titers kinetics. Conclusions The decline of serum HBV DNA and hepatitis B surface antigen at the 4th week can be used to predict the response to PEG-IFNα 2a in patients with HBeAg positive chronic hepatitis B.
H epatitis B virus (HBV) infection has become
one of the most serious public health threats in recent years. Two billion people worldwide have been infected with HBV, and more that 350 million have become victims of chronic hepatitis B (CHB).
1 Several nucleos(t)ide analogues are currently approved for the treatment of HBV infection with a high efficacy in suppressing HBV replication. However, a long duration of treatment is required to maintain viral suppression, and the major question of whether oral therapy can ever be stopped remains unanswered. 2 The American Association for the Study of Liver Diseases practice guidelines have advocated pegylated interferon (PEG-IFN) α-2a as a potential first-line therapy in hepatitis B e antigen (HBeAg)-positive patients. 3 The advantages of PEG-IFN therapy include a limited treatment course, a higher rate of Department of Infectious Diseases, Huashan Hospital, Fudan University, 12 Middle Urumqi Road, Shanghai 200040, China. Correspondce: Guang-feng Shi, Fax: +86-21-62480170. E-mail: gfshi@ shmu.edu.cn HBeAg seroconversion, a 20% to 30% rate of sustained virological response (SVR), the potential for hepatitis B surface antigen (HBsAg) loss or seroconversion, and lack of resistance development. The disadvantages of PEG-IFN therapy include its side effects, lower antiviral potency of PEG-IFN compared with analogues, the substantial risk of relapse after cessation of therapy and need of injection. Recently, on-treatment serum HBeAg levels were used in HBeAg-positive patients as a quantitative tool to predict SVR to PEG-IFN and showed high negative predictive values (NPVs) at the 12th week and 24th week of therapy. 4 In HBeAg-negative CHB patients, a recent pilot study including a small number of patients revealed early serum HBsAg drop has high predictive values of SVR to PEG-IFN.
5 Plasmacytoid dendritic cells (pDCs) are important contributers in host defence as they produce large amounts of typeⅠIFNs, a critical early step for the innate immune system to control viral replication. This study was aimed to assess on-treatment serum HBsAg and HBV DNA kinetics in HBeAg-positive CHB patients to predict efficacy of PEG-IFN in early phase of treatment. Moreover, relationships were assessed between either IFN (endogenous or not) or neutralizing antibody to PEG -IFN levels and serum HBsAg kinetics or virological response to a first-line treatment with PEG-IFN.
PATIENTS AND METHODS

Patient population
This was a retrospective study of 41 patients with CHB with no prior history of treatment with immunomodulatory or antiviral drugs, who were followed up between July, 2010 and October, 2011 at Huashan Hospital, Fudan University. Fortyone treatment-naive HBeAg-positive patients were evaluated. CHB was documented by the presence of HBsAg in serum for more than 6 months, and by persistently elevated serum alanine aminotransferase (ALT). Patients were treated with PEG-IFN α-2a at a dose of 180 μg/week for at least 24 weeks. Thereafter they were scheduled for follow-up visits every 4 weeks. Their treatment response was assessed including normalization of serum ALT, decrease in serum HBV DNA level, and loss of HBeAg. At the year 2000 and 2006 in NIH conferences on management of hepatitis B, it was proposed that responses to antiviral therapy of chronic hepatitis B should be categorized as biochemical response (BR) and virologic response (VR). In IFN treatment, VR is identified as a decrease of more than 2 log 10 (100-fold) in serum HBV DNA at first 6 months treatment. Informed consents were obtained from all patients before treatment. Experiments and procedures were in accordance with the Helsinki Declaration of 1975, and approved by the Human Ethics Committee of Shanghai Fudan University.
Measurement of liver function and serological HBV markers
Liver function detection such as serum albumin, total bilirubin (TBil) and ALT were performed by standard methods in a clinical setting. Hepatitis B serological markers were tested using a commercially available radioimmunoassay (Abbott). The level of HBV DNA was quantified using a DNA assay (PG Biotech; with a lower limit of detection of 500 copies/ml).
Flow cytometric analysis
Expression of surface markers was analyzed by flow cytometry using conjugated monoclonal mouse antihuman antibodies: fluorescein isothiocyanate (FITC) anti-human Lin1, phycoerythrin (PE) -Cy5 antihuman CD23, and APC anti-human HLA-DR (eBiosciences). Flow cytometry analysis was performed on FACSCalibur (BD Biosciences) instruments and analyzed by FlowJo software (Tree Star Inc.).
ELISA
IFN levels and neutralizing antibody to IFNα 2a
were measured on stored sera at baseline and the 4th, the 12th and the 24th week, using a commercial quantitative sandwich ELISA kit (Bender MedSystems Diagnostics, Vienna, Austria) according to the manufacturer's instructions. The absorbance was read at 450 nm by an ELISA plate reader.
Statistical analysis
Quantitative variables were shown as median with ranges, and categorical variables as absolute and relative frequencies. Comparisons between different groups were performed by the Wilcoxon Ranksum test and student's t test. Correlation between serum HBsAg and HBV DNA levels was performed through Spearman rank correlation. All tests were two-sided and used a significant level of 0.05. Data handling and analysis were performed with STATA software, version 7.0.
RESULTS
Forty-one treatment-naive patients with CHB were recruited into the study. Baseline characteristics of them are shown in Table 1 . The majority of patients was Asian and infected with genotype B or C HBV. All 41 HBeAg-positive patients were in an immune clearance phase of disease, defined by persistently elevated serum ALT. Serological detection for hepatitis C virus, hepatitis D virus, and human immunodeficiency virus were negative in all patients.
Biochemical response
To t a l o f 1 9 p a t i e n t s ( 4 6 . 3 % ) a c h i e v e d A LT normalization at the 24th week. The median ALT levels at the 12th week and the 24th week were significantly lower compared to baseline (Z = 5.189, P < 0.0001 and Z = 5.801, P < 0.0001 at the 12th week and 24th week, respectively, Table 2 , Figure 1 ).
Virological response
Total of 4 patients (9.7%) had undetectable HBV DNA levels at the 24th week. And 23 patients (56.1%) achieved virological response (VR). The median HBV DNA levels at the 4th, the 12th and the 24th week were significantly lower compared to baseline (Z = 4.620, P < 0.0001; Z = 5.701, P < 0.0001 and Z = 6.131, P < 0.0001 at the 4th, 12th and 24th week, respectively, Notes: A, the ALT levels (U/L) at the 12th and 24th week were significantly lower compared to the baseline (P < 0.0001 and P < 0.0001, respectively). B, the HBV DNA levels (log 10 copies/ml) at the 4th, 12th and 24th week were significantly lower compared to the baseline (P < 0.0001, P < 0.0001 and P < 0.0001, respectively). Data were not normally distributed and therefore were transformed into log 10 . C, the HBsAg levels (log 10 IU/ml) at the 4th, 12th and 24th week were significantly lower compared to the baseline (P = 0.0065, P = 0.0003 and P < 0.0001, respectively). Data were not normally distributed and therefore were transformed into log. D, IFN-α concentration (pg/ml) at the 4th, 12th and 24th week were significantly higher compared to the baseline (P < 0.0001, P < 0.0001 and P < 0.0001, respectively). E, IFN-α antibodies titers (ng/ml) were not significantly different at each time point. F, PDC/PBMC (%) at the 4th week was significantly higher compared to the baseline (P = 0.0094). But PDC/PBMC at the 12th and 24th week were significantly lower compared to the baseline (P = 0.0358 and P = 0.0051, respectively). Notes: A, IFN-α concentration in ALT normal group was significantly higher compared to that in ALT abnormal group at the 24th week (Z = 2.171, P < 0.05). B, a decrease of HBsAg level at the 4th week was positively correlated with that at the 12th week (r = 0.4868, P = 0.0023). C, a decrease of HBsAg level at the 4th week was positively correlated with that at the 24th week (r = 0.4251, P = 0.0109). D, a decrease of HBV DNA level at the 4th week was positively correlated with that at the 12th week (r = 0.8202, P < 0.0001). E, a decrease of HBV DNA level at the 4th week was positively correlated with that at the 24th week (r = 0.6838, P < 0.0001). F, a decrease of HBsAg level at the 24th week was positively correlated with the decrease of HBV DNA level at the 24th week (r = 0.5262, P = 0.0024). The numbers outside and inside of the brackets represent corresponding values of medians and the ranges at baseline, the 4th week, 12th week and 24th week, respectively; * measns values compared to the baseline, P < 0.05. Table 2 ). A decrease of HBV DNA level at the 4th week was positively correlated with the decrease of HBV DNA level at the 12th week and the 24th week (r = 0.8202, P < 0.0001 and r = 0.6838, P < 0.0001, respectively, Figure 2) . A decrease of HBV DNA level at the 12th week was positively correlated with the decrease of HBV DNA level at the 24th week (r = 0.7493, P < 0.0001). The cutoff of 1.2 log 10 copies/ml decrease (sensitivity 75%, specificity 100%) in serum HBV DNA at the 4th week of therapy will encourage physicians to continue to use PEG-IFN in patients whose serum HBV DNA may decrease more than 2 log 10 copies/ml at the 24th week of therapy (Figure 3 ).
Serum HBsAg kinetics
Totally, serum HBsAg levels of 2 patients (4.9%) were undetectable at the 24th week, and 11 patients (26.8%) had a decrease of 1 log 10 copies/ml and 4 patients (9.8%) had a decrease of 2 log 10 copies/ml in serum HBsAg levels at the 24th week. The HBsAg levels at the 4th, the 12th and the 24th week were significantly lower compared to the baseline (t = 2.801, P = 0.0065; t = 3.773, P = 0.0003 and Z = 3.882, P < 0.0001 at the 4th, 12th and 24th week, respectively, Table 2 ). A decrease of HBsAg level at the 4th week was positively correlated with the decrease of HBsAg level at the 12th week and the 24th week (r = 0.4868, P = 0.0023 and r = 0.4251, P = 0.0109, respectively, Figure 2 ). A decrease of HBsAg level at the 12th week was positively correlated with the decrease of HBsAg level at the 24th week (r = 0.5733, P = 0.0001). A decrease of HBsAg level at the 24th week was positively correlated with the decrease of HBV DNA level at the 24th week (r = 0.5262, P = 0.0024).
HBeAg loss
Among the studied population (n = 41), HBeAg loss occurred in 3 patients (7.3%) at the 12th week and 6 patients (14.6%) at the 24th week, respectively.
IFN-α concentration
Serum IFN-α concentration at the 4th, 12th and 24th week were significantly higher compared to baseline (t = 9.481, P < 0.0001; Z = -6.862, P < 0.0001 and Z = -6.969, P < 0.0001 at the 4th, 12th and 24th week, respectively). IFN-α concentration at the 12th week and 24th week were significantly higher compared to that at the 4th week (Z = -4.316, P < 0.0001 and Z = -3.830, P = 0.0001 at the 12th and 24th week, respectively). IFN-α concentration at the 24th week was not significantly different with that of the 12th week (Z = 0.367, P = 0.7136, Table 2 ). IFN-α concentration in ALT normal group was significantly higher compared to that in ALT abnormal group at the 24th week (Z = 2.171, P = 0.0300). IFN-α concentration in VR group was not significantly different compared to that in non-VR group at the 24th week (Z = 0.205, P = 0.8377). IFN-α concentrations in patients with a decrease > 1 log 10 IU/ml in serum HBsAg showed no significant difference compared to that in patients without HBsAg decrease > 1 log 10 IU/ml group at the 24th week (Z = 1.205, P = 0.2282).
IFN-α antibodies titers
There was no significant difference among each time point (Table 2) . IFN-α antibodies titers in ALT normal group was not significantly different compared to that in ALT abnormal group at the 24th week (Z = -0.565, P = 0.5720). IFN-α antibodies titers in VR group was not significantly different compared to that in non-VR group (Z = 0.274, P = 0.7839). IFN-α antibodies titers in a decrease over 1 log 10 IU/ml in serum HBsAg group was not significantly different compared to that in a decrease less than 1 log 10 IU/ml group at the 24th week Notes: The cutoff of 1.2 log 10 copies/ml decrease (sensitivity 75%, specificity 100%) in serum HBV DNA at the 4th week of therapy will encourage physicians to continue to use PEG-IFN in patients whose serum HBV DNA will decrease more than 2 log 10 copies/ml at the 24th week of therapy.
(Z = 0.880, P = 0.3790). IFN-α antibodies titers was not significantly different between male and female patients (Z = -0.733, P = 0.4635).
PDCs/PBMC
PDC/PBMC was detected by flow cytometric analysis (Figure 4 ). PDC/PBMC at the 4th, 12th and 24th week were significantly lower compared to that at the baseline (Z = -2.596, P = 0.0094; Z = 2.099, P = 0.0358 and Z = 2.799, P = 0.0051 at the 4th, 12th and 24th week, respectively, Table 2 and Figure 1 ).
DISCUSSION
In our study, we found serum IFN-α concentration in ALT normal group was significantly higher compared to that in ALT abnormal group at the 24th week, but it had no relationship with HBV DNA or HBsAg titer kinetics. PDC/PBMC at the 4th, 12th and 24th week were significantly lower compared to that at the baseline, thus serum IFN-α concentration did not seem as endogenous for PDC/PBMC continues decrease in the treatment, and was likely to be affected by PEG-IFN. IFN-α antibodies seems not very important in PEG-IFN treatment and not as its role in interferon treatment.
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It had no relationship with ALT normalization, HBV DNA or HBsAg titer kinetics, or IFN-α concentration. Some scholars have found that a decrease < 60% of baseline levels of HBsAg at the 12th week was considered as an independent predictive factor for HBeAg seroconversion (OR = 45.7, P < 0.05) at the 96th week. Serum HBsAg levels may be helpful for predicting the response to PEG-IFN therapy in HBeAg-positive chronic hepatitis B patients.
10 And a quantitative serum HBsAg level at the 12th week of therapy can be used for the early prediction of sustained response to PEG-IFN therapy in HBeAgnegative CHB patients infected with genotype B or C.
11 Moreover, the correlation between quantitative HBsAg titer, and serum and intrahepatic markers of HBV replication differs between patients with HBeAgpositive and HBeAg-negative CHB. These findings suggested that quantitative HBsAg titer can be taken as a clinical biomarker.
12 Recent data suggested that quantitative determination of HBsAg level may provide a useful insight into the likelihood of eventual HBsAg seroconversion.
13 These findings are in accordance with the dual antiviral and immunomodulatory effects of PEG-IFN, which result in the suppression of viral replication, but also the clearance of infected hepatocytes. This is supported by the finding that the reduction of serum HBsAg levels parallels the decline of intrahepatic covalently closed circular DNA.
14 In our study, it would be of great clinical relevance to identify as early as possible those patients who are likely to develop EVR, and more importantly, relapsers and nonresponders who may be benefited from being switched to an alternate treatment strategy.
In lamivudine-treated patients, early suppression of viral load was linked to greater rates of HBeAg seroconversion, even when advanced liver disease was present. 15 In addition, it was demonstrated that a drop in viral load to HBV DNA levels below 2000 IU/ml at the 4th week could predict an ideal outcome, defined as combined virological and biochemical response at 5th year. 16 However, in a large randomized multicenter Notes: Expression of surface markers was analyzed by flow cytometry using conjugated monoclonal mouse anti-human antibodies: fluorescein isothiocyanate (FITC) anti-human Lin1, phycoerythrin (PE) -Cy5 anti-human CD23, and APC anti-human HLA-DR (eBio-sciences). Red color points represent PDC-iso, and blue color points represent PBMC of patients, and PDC was counted in Q1.
study of PEG-IFN α-2b with or without LAM, a 1log 10 drop in serum HBV DNA levels at the 32th week of PEG-IFN α-2b monotherapy was predictive of HBeAg loss in genotype A patients only. Earlier predictions were not associated with sustained response in that study. 17 One model strongly supports individual decision making on treatment (dis)continuation in patients with HBeAg positive chronic hepatitis B. It is recommended that PEG-IFN treatment is stopped at the 24th week if HBV DNA declined < 2 log 10 .
18 However, we found that the decrease of HBV DNA level at the 4th week was positively correlated with the decrease of HBV DNA level at the 12th and 24th week (r = 0.8202, P < 0.0001 and r = 0.6838, P < 0.0001, respectively). During hepatitis C treatment, a rapid virological response (RVR), defined as undetectable HCV RNA at the 4th week of treatment, using a sensitive detection with a lower limit detection of 50 IU/ml, predicts a high likelihood of achieving an SVR. An early virological response (EVR) is defined as a > 2 log 10 reduction or complete absence of serum HCV RNA at the 12th week of therapy compared with the baseline level. Failure to achieve an EVR is the most accurate predictor of not achieving an SVR. 19 In our study, we found viral kinetics monitoring is thus useful for predicting whether or not an EVR is likely to happen.
In our study, we also found high predictive values of on-treatment serum HBV DNA kinetics to predict EVR. The cutoff of 1.2 log 10 copies/ml decrease (sensitivity 75%, specificity 100%) in serum HBV DNA at the 4th week of therapy will encourage physicians to continue PEG-IFN in patients whose serum HBV DNA will decrease more than 2 log 10 copies/ml at the 24th week of therapy. By analogy with the early virological response in hepatitis C patients treated with PEG-IFN and ribavirin, this early serum HBV DNA kinetics may be used as an early serological response, which allows a change in the paradigm of therapy in HBeAg-positive patients. It is of note that the potential value of serum HBV DNA kinetics at the 4th week during treatment for predicting response to PEG-IFN was suggested in HBeAg-positive patients.
In conclusion, serum HBsAg and HBV DNA level at the 4th week seems to be an excellent on-treatment quantitative marker for predicting EVR and identifying who will most likely benefit from PEG-IFN treatment. Further studies using PEG-IFN with or without potent analogues are warranted to confirm these data on a large scale.
